Zheng Quan Ri Bao·2026-03-09 04:41Core Viewpoint - Fosun International Limited announced plans for share buybacks and stock purchases by major shareholders, signaling confidence in the company's long-term prospects and strategic direction [1][2]. Group 1: Shareholder Actions - Fosun's major shareholders and executives plan to increase their holdings by up to HKD 500 million within 12 months after the 2025 annual results announcement [1]. - The company intends to repurchase shares in the open market for a total amount not exceeding HKD 1 billion from the 2025 results announcement until the 2026 annual general meeting [1]. Group 2: Financial Performance and Strategy - Fosun International issued a profit warning, projecting a loss of approximately RMB 21.5 billion to RMB 23.5 billion for the fiscal year 2025, primarily due to one-time non-cash impairment charges [2]. - The company is focusing on its core businesses and has implemented a strategy of "streamlining and focusing on main operations," which includes significant asset impairment to improve transparency and asset quality [2][4]. Group 3: Core Business Growth - The core sectors of Fosun, including healthcare and insurance, are showing improved asset and profit quality, with notable growth in revenue and net profit [4][5]. - For instance, Fosun Pharma reported revenue of RMB 29.393 billion and a net profit of RMB 2.523 billion for the first three quarters of 2025, reflecting a year-on-year growth of 25.5% [4]. - In the insurance sector, Fosun's Portuguese insurance unit received an A rating from S&P, with a net profit of EUR 1.7 million for the first three quarters of 2025, up 11.7% year-on-year [5]. Group 4: Future Outlook - Fosun's management expressed confidence in achieving a profit target of RMB 10 billion over the next three to five years while optimizing its financial structure and reducing total liabilities to below RMB 60 billion [5]. - The company anticipates entering a new development cycle in 2026, with a positive outlook for future growth [5].